Enterprise Europe Network

A novel human tumor endothelial marker 1 targeting antibody-drug conjugate for treatment of cancer

Country of origin:
Country: 
ITALY
Opportunity:
External Id: 
TOIT20191215001
Published
16/12/2019
Last update
30/01/2020
Expiration date
30/01/2021

Keywords

Partner keyword: 
Cytology, Cancerology, Oncology
Pharmaceutical Products / Drugs
Oncology
EXPRESS YOUR INTEREST

Summary

Summary: 
An Italian SME specialized in drug discovery has developed and patented a human tumor endothelial marker 1 (TEM1) targeting antibody-drug conjugate (ADC) for treating cancer. This molecule has shown therapeutic efficacy combined with a good safety profile. The company is looking for pharmaceutical companies or investors for financial or license agreement to further develop the product in clinical trials. A research cooperation agreement is also foreseen.

Description

Description: 

TEM1, also named endosialin is a transmembrane protein widely expressed on the surface of cells of mesenchymal origin, including pericytes and activated fibroblasts which are thought to play a key role in the development of tumor neovascular networks and stromal interaction. Although TEM1 expression is dramatically reduced during adult life, it may be upregulated during malignancy such as sarcoma and neuroblastoma. Therefore, TEM1 is an ideal target for an ADC approach.

An Italian SME specialized in drug discovery and located in Central Italy has developed and patented an anti-TEM1 monoclonal antibody which has been used to generate a TEM1 targeting ADC. Compared with the naked antibody, the ADC has shown high in vivo activity against osteosarcoma xenografts in mice. The ADC has a good safety profile in treated animals.

The product is in pre-clinical stage of development. In order to submit the application for phase 1 trial, the following steps have to be performed: (i) generation of a stable antibody producing cell line and a master cell bank (ii) production of drug substance batch and performing a toxicology study (iii) production of clinical drug substance batches.

Pharmaceutical companies or investors for financial or license agreement to further develop the product in clinical trials are sought. The company is also interested in a research cooperation agreement.

Advantages & innovations

Cooperation plus value: 
The company has generated a novel ADC by coupling its proprietary anti-TEM1 humanized monoclonal antibody with a potent cytotoxic antitumor drug through a linker. Compared with the naked antibody, the resulting ADC was more effective in inducing long-lasting regression of human sarcoma established in nude mice. Also, the product showed a good safety profile combined with favorable pharmacokinetics (PK). TEM1 is overexpressed in more than 50% of human sarcoma and neuroblastoma. Therefore, possible indications in oncology include these two forms of cancer.

Stage of development

Cooperation stage dev stage: 
Under development/lab tested

Partner sought

Cooperation area: 
The company is looking for pharmaceutical companies or investors (VC, Banks, Private Investors) interested in financial or license agreement to further develop the product in clinical trials. A research cooperation agreement with a technological partner (pharmaceutical company, R&D insititution) with expertise and interest in therapeutic antibody or/and ADC technology could also be considered. During the cooperation, the partner is expected to set-up and upscaling manufacturing process of the anti-TEM1 antibody in accordance with good manufacturing practice (GMP) and regulatory, among others.

Type and size

Cooperation task: 
R&D Institution,>500 MNE,251-500,SME 51-250